Author
Listed:
- Sandhya Bangaru
(Vanderbilt University Medical Center)
- Heng Zhang
(The Scripps Research Institute
Institute of High Energy Physics, Chinese Academy of Sciences)
- Iuliia M. Gilchuk
(Vanderbilt University Medical Center)
- Thomas G. Voss
(Vanderbilt University Medical Center
Vanderbilt University Medical Center)
- Ryan P. Irving
(Vanderbilt University Medical Center)
- Pavlo Gilchuk
(Vanderbilt University Medical Center)
- Pranathi Matta
(Vanderbilt University Medical Center)
- Xueyong Zhu
(The Scripps Research Institute)
- Shanshan Lang
(The Scripps Research Institute)
- Travis Nieusma
(The Scripps Research Institute)
- Juergen A. Richt
(College of Veterinary Medicine, Kansas State University)
- Randy A. Albrecht
(at Icahn School of Medicine at Mount Sina)
- Hillary A. Vanderven
(Peter Doherty Institute for Infection and Immunity, University of Melbourne)
- Robin Bombardi
(Vanderbilt University Medical Center)
- Stephen J. Kent
(Peter Doherty Institute for Infection and Immunity, University of Melbourne)
- Andrew B. Ward
(The Scripps Research Institute)
- Ian A. Wilson
(The Scripps Research Institute
The Scripps Research Institute)
- James E. Crowe
(Vanderbilt University Medical Center
Vanderbilt University Medical Center
Vanderbilt University Medical Center)
Abstract
The high rate of antigenic drift in seasonal influenza viruses necessitates frequent changes in vaccine composition. Recent seasonal H3 vaccines do not protect against swine-origin H3N2 variant (H3N2v) strains that recently have caused severe human infections. Here, we report a human VH1-69 gene-encoded monoclonal antibody (mAb) designated H3v-47 that exhibits potent cross-reactive neutralization activity against human and swine H3N2 viruses that circulated since 1989. The crystal structure and electron microscopy reconstruction of H3v-47 Fab with the H3N2v hemagglutinin (HA) identify a unique epitope spanning the vestigial esterase and receptor-binding subdomains that is distinct from that of any known neutralizing antibody for influenza A H3 viruses. MAb H3v-47 functions largely by blocking viral egress from infected cells. Interestingly, H3v-47 also engages Fcγ receptor and mediates antibody dependent cellular cytotoxicity (ADCC). This newly identified conserved epitope can be used in design of novel immunogens for development of broadly protective H3 vaccines.
Suggested Citation
Sandhya Bangaru & Heng Zhang & Iuliia M. Gilchuk & Thomas G. Voss & Ryan P. Irving & Pavlo Gilchuk & Pranathi Matta & Xueyong Zhu & Shanshan Lang & Travis Nieusma & Juergen A. Richt & Randy A. Albrech, 2018.
"A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA,"
Nature Communications, Nature, vol. 9(1), pages 1-15, December.
Handle:
RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04704-9
DOI: 10.1038/s41467-018-04704-9
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-04704-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.